A detailed history of Barclays PLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 130,381 shares of CLDX stock, worth $3.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130,381
Previous 130,381 -0.0%
Holding current value
$3.28 Million
Previous $4.43 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$32.06 - $44.56 $2.44 Million - $3.4 Million
76,207 Added 140.67%
130,381 $4.43 Million
Q2 2024

Aug 14, 2024

SELL
$32.76 - $42.56 $410,810 - $533,702
-12,540 Reduced 18.8%
54,174 $2 Million
Q1 2024

May 15, 2024

SELL
$35.22 - $51.88 $2.79 Million - $4.11 Million
-79,180 Reduced 54.27%
66,714 $2.8 Million
Q4 2023

Feb 15, 2024

BUY
$22.61 - $40.65 $54,964 - $98,820
2,431 Added 1.69%
145,894 $5.79 Million
Q3 2023

Nov 07, 2023

SELL
$25.45 - $37.46 $729,676 - $1.07 Million
-28,671 Reduced 16.66%
143,463 $3.95 Million
Q2 2023

Aug 03, 2023

BUY
$30.29 - $38.28 $1.91 Million - $2.42 Million
63,110 Added 57.89%
172,134 $5.84 Million
Q1 2023

May 04, 2023

SELL
$34.78 - $47.43 $259,006 - $353,211
-7,447 Reduced 6.39%
109,024 $3.92 Million
Q4 2022

Feb 13, 2023

SELL
$27.78 - $45.38 $781,062 - $1.28 Million
-28,116 Reduced 19.45%
116,471 $5.19 Million
Q3 2022

Nov 03, 2022

BUY
$22.7 - $37.57 $1.08 Million - $1.78 Million
47,500 Added 48.93%
144,587 $4.06 Million
Q2 2022

Aug 12, 2022

SELL
$20.5 - $37.33 $2.25 Million - $4.09 Million
-109,613 Reduced 53.03%
97,087 $2.62 Million
Q1 2022

May 16, 2022

BUY
$27.64 - $39.32 $1.84 Million - $2.62 Million
66,748 Added 47.69%
206,700 $7.04 Million
Q4 2021

Feb 14, 2022

BUY
$35.68 - $56.27 $3.57 Million - $5.64 Million
100,184 Added 251.92%
139,952 $5.41 Million
Q3 2021

Nov 09, 2021

BUY
$28.95 - $55.99 $519,449 - $1 Million
17,943 Added 82.21%
39,768 $2.15 Million
Q2 2021

Aug 13, 2021

SELL
$20.71 - $35.37 $693,246 - $1.18 Million
-33,474 Reduced 60.53%
21,825 $730,000
Q1 2021

May 13, 2021

BUY
$16.19 - $29.91 $887,195 - $1.64 Million
54,799 Added 10959.8%
55,299 $1.14 Million
Q4 2020

Feb 11, 2021

SELL
$14.99 - $22.75 $5,486 - $8,326
-366 Reduced 42.26%
500 $9,000
Q3 2020

Nov 12, 2020

BUY
$9.65 - $15.19 $8,337 - $13,124
864 Added 43200.0%
866 $13,000
Q2 2020

Aug 12, 2020

BUY
$1.61 - $13.41 $3 - $26
2 New
2 $0
Q4 2019

Feb 10, 2020

SELL
$2.11 - $2.8 $54 - $72
-26 Closed
0 $0
Q3 2019

Nov 14, 2019

SELL
$2.05 - $2.75 $7,994 - $10,725
-3,900 Reduced 99.34%
26 $0
Q2 2019

Aug 14, 2019

SELL
$2.43 - $5.09 $12,636 - $26,468
-5,200 Reduced 56.98%
3,926 $10,000
Q1 2019

May 15, 2019

BUY
$3.45 - $10.35 $31,484 - $94,454
9,126 New
9,126 $45,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.18B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.